Oruka Therapeutics (NASDAQ:ORKA) CEO Sells 75,000 Shares of Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) CEO Lawrence Otto Klein sold 75,000 shares of the stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $91.83, for a total value of $6,887,250.00. Following the sale, the chief executive officer directly owned 925,580 shares of the company’s stock, valued at approximately $84,996,011.40. The trade was a 7.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Lawrence Otto Klein also recently made the following trade(s):

• On Monday, June 15th, Lawrence Otto Klein sold 1,729 shares of Oruka Therapeutics stock. The stock was sold at an average price of $69.69, for a total transaction of $120,494.01.

Oruka Therapeutics Price Performance

ORKA traded down $0.51 during trading on Tuesday, reaching $92.11. The company had a trading volume of 596,157 shares, compared to its average volume of 1,116,787. Oruka Therapeutics, Inc. has a 12 month low of $14.66 and a 12 month high of $115.51. The business’s fifty day moving average price is $94.75 and its 200 day moving average price is $68.17. The company has a market cap of $6.10 billion, a P/E ratio of -45.37 and a beta of -0.34.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.04). As a group, sell-side analysts predict that Oruka Therapeutics, Inc. will post -2.33 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ORKA has been the subject of a number of research reports. BTIG Research reiterated a “buy” rating and set a $151.00 target price on shares of Oruka Therapeutics in a report on Tuesday, August 11th. Piper Sandler restated an “overweight” rating and issued a $180.00 price target on shares of Oruka Therapeutics in a report on Tuesday, June 2nd. UBS Group upped their price objective on Oruka Therapeutics from $100.00 to $130.00 and gave the stock a “buy” rating in a research report on Wednesday, July 1st. Guggenheim reiterated a “buy” rating and set a $200.00 price objective on shares of Oruka Therapeutics in a report on Tuesday, August 11th. Finally, Weiss Ratings raised Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 15th. Ten investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Oruka Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $134.30.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in ORKA. Legal & General Group Plc acquired a new stake in Oruka Therapeutics in the 2nd quarter valued at $28,000. Nykredit A S bought a new stake in Oruka Therapeutics during the 2nd quarter worth about $29,000. BNP Paribas Financial Markets boosted its stake in shares of Oruka Therapeutics by 464.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock worth $31,000 after buying an additional 2,306 shares during the last quarter. Royal Bank of Canada boosted its stake in shares of Oruka Therapeutics by 47.2% during the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after buying an additional 365 shares during the last quarter. Finally, Los Angeles Capital Management LLC bought a new position in shares of Oruka Therapeutics in the 4th quarter valued at about $37,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical?stage biopharmaceutical company focused on the development of novel peptide?based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell?permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.